Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Aug, 2013 | Pubmed ID: 23757356